Dr. Lewis-Hall has spent 40+ years on the frontlines of healthcare as a clinician, researcher, and leader in the biopharmaceutical and life sciences industries.
She was most recently a top executive at Pfizer, Inc.
The Council provides strategic advice, assists with raising funds, and builds awareness.
The Foundation and the American Institute of Ultrasound in Medicine's Future Fund will host a free virtual workshop series entitled, “Detecting, Mapping, and Quantifying Bubble Activity in Therapeutic Ultrasound.”
Join us Fridays from September 24 through October 29 at 10:00 am Eastern.
The Foundation funded three projects that have been completed in the first half of 2021.
Topics include improved imaging for focused ultrasound brain treatments, treating low-grade tumors in dogs, and a preclinical pancreatic cancer model that responded to histotripsy.
Focused ultrasound research on transcranial neuromodulation was featured on “From Brain to Behaviour,” which highlights the most exciting brain research published by Nature Communications.
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) funded this research.
One trial comparing focal ablation to radical prostatectomy in intermediate-risk prostate cancer patients found fewer side effects at one year in the Focal One group.
Another large comparative trial found a significantly higher salvage-treatment-free survival rate in HIFU patients compared to radical prostatectomy.
Insightec’s CEO Maurice Ferré, MD, and Chase Koch, President of Koch Disruptive Technologies, held a fireside chat at the Technology Policy Institute’s Aspen Forum.
The discussion addressed focused ultrasound’s evolution as a noninvasive therapy and how both companies are unlocking the technology’s potential to improve millions of lives.
